What is the controversy over the spinal muscular atrophy drug in Kerala? Explained
The Kerala government is facing backlash after switching from a branded drug to a generic version for the treatment of Spinal Muscular Atrophy (SMA). Parents and political groups are concerned about the efficacy and labeling of the new medication, prompting a public debate on healthcare accessibility.
Why it matters
This highlights the tension between cost-saving measures in public healthcare and the quality of life for patients with rare, life-threatening diseases.
What is the controversy over the spinal muscular atrophy drug in Keralam? Explained SMA issue explainer left SMA is a rare, life-threatening genetic disorder that progressively weakens muscles, severely impairing both mobility and respiratory function. Image used for representational purposes only Getty Images Getty Images https://th-i.thgim.com/public/incoming/8ay8w4/article71619537.ece/alternates/FREE_1200/IMG_BL3012_Pulse_Anchor_2_1_R9DPCMH4.jpg Oksana Horiun Spinal Muscular atrophy ribbon. Vector cartoon illustration of hands with a heart shape holding a ribbon. After the government switched the drug in its SMA programme from branded to generic, parents of children living with SMA have been asking for a switch back to the branded version; meanwhile the label on a drug bottle has sparked concerns, and political parties have now latched on to the issue The story so far An initiative launched by Keralam government to make the treatment for Spinal Muscular Atrophy (SMA) accessible to more patients is now courting controversy.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in